Treatment of Unresectable, Inoperable, or Metastatic Giant Cell Tumor of Bone
Clinical Scenario
This protocol applies to patients with giant cell tumor of bone (GCTB) that is unresectable or inoperable, to those with metastatic disease, and to patients who have undergone resection but are left with significant functional impairment. Pregnant patients are outside the scope of this protocol.
Treatment Approach
The current standard for this population centres on a targeted monotherapy given at extended intervals to reduce the risk of complications. A more cost-effective alternative agent exists and may be particularly relevant in resource-limited settings.
Summary only — complete regimen in full protocol
Clinical Goals
Cessation of tumor enlargement and relief of symptoms through bone formation and possible tumor shrinkage.
References
DOI: 10.3390/curroncol31040157
- At present, this agent is indicated for unresectable GCTB or in case of significant functional impairment following resection.
- Denosumab monotherapy once every 3 months is currently the standard strategy for inoperable patients and those with metastatic GCTB.
- Denosumab is contraindicated for pregnant patients.
- Therefore, extending the dosing period (120 mg every 3 months) is recommended to reduce the incidence of complications.
- Therefore, ZA may be an alternative treatment option, particularly in developing countries.
- After treatment with denosumab, tumor enlargement ceases in 99% of cases.
- and all symptoms were relieved via bone formation and possible tumor shrinkage.
View source ↗